Summary
THAM (trometamol; tris-hydroxymethyl aminomethane) is a biologically inert amino alcohol of low toxicity, which buffers carbon dioxide and acids in vitro and in vivo. At 37°C, the pK (the pH at which the weak conjugate acid or base in the solution is 50% ionised) of THAM is 7.8, making it a more effective buffer than bicarbonate in the physiological range of blood pH. THAM is a proton acceptor with a stoichiometric equivalence of titrating 1 proton per molecule.
In vivo, THAM supplements the buffering capacity of the blood bicarbonate system, accepting a proton, generating bicarbonate and decreasing the partial pressure of carbon dioxide in arterial blood (paCO2). It rapidly distributes through the extracellular space and slowly penetrates the intracellular space, except for erythrocytes and hepatocytes, and it is excreted by the kidney in its protonated form at a rate that slightly exceeds creatinine clearance. Unlike bicarbonate, which requires an open system for carbon dioxide elimination in order to exert its buffering effect, THAM is effective in a closed or semiclosed system, and maintains its buffering power in the presence of hypothermia.
THAM rapidly restores pH and acid-base regulation in acidaemia caused by carbon dioxide retention or metabolic acid accumulation, which have the potential to impair organ function.
Tissue irritation and venous thrombosis at the site of administration occurs with THAM base (pH 10.4) administered through a peripheral or umbilical vein; THAM acetate 0.3 mol/L (pH 8.6) is well tolerated, does not cause tissue or venous irritation and is the only formulation available in the US. In large doses, THAM may induce respiratory depression and hypoglycaemia, which will require ventilatory assistance and glucose administration.
The initial loading dose of THAM acetate 0.3 mol/L in the treatment of acidaemia may be estimated as follows: THAM (ml of 0.3 mol/L solution) = lean body-weight (kg) × base deficit (mmol/L). The maximum daily dose is 15 mmol/kg for an adult (3.5L of a 0.3 mol/L solution in a 70kg patient).
When disturbances result in severe hypercapnic or metabolic acidaemia, which overwhelms the capacity of normal pH homeostatic mechanisms (pH ≤7.20), the use of THAM within a ‘therapeutic window’ is an effective therapy. It may restore the pH of the internal milieu, thus permitting the homeostatic mechanisms of acid-base regulation to assume their normal function. In the treatment of respiratory failure, THAM has been used in conjunction with hypothermia and controlled hypercapnia. Other indications are diabetic or renal acidosis, salicylate or barbiturate intoxication, and increased intracranial pressure associated with cerebral trauma. THAM is also used in cardioplegic solutions, during liver transplantation and for chemolysis of renal calculi.
THAM administration must follow established guidelines, along with concurrent monitoring of acid-base status (blood gas analysis), ventilation, and plasma electrolytes and glucose.
Article PDF
Similar content being viewed by others
References
Gomori G. Buffers in the range of pH 6.5 to 9.6. Proc Soc Exp Biol Med 1946; 62: 33–4
Bates R, Bower V. Alkaline solutions for pH control. Anal Chem 1956; 28: 1322–4
Fossum J, Markunas P, Riddick J. Tris (hydroxymethyl) aminomethane as an acidimetric standard. Anal Chem 1951; 23: 491–3
Riddick J. Amine buffers as acidimetric standards. Ann NY Acad Sci 1961; 92(2): 357–65
Benesch R, Benesch R. The stability of the silver complex of tris (hydroxymethyl)aminomethane. J Am Chem Soc 1955; 77: 2749–50
Nahas G, Jordan E, Ligou J. Effects of a ‘CO2 buffer’ on hypercapnia of apneic oxygenation. Am J Physiol 1959; 197: 1308–16
Helwig H. Metabolic effects of trometamol with special reference to pediatrics [in German]. New York: Springer-Verlag, 1974
Nahas GG. The pharmacology of Tris (hydroxymethyl)aminomethane (THAM). Pharmacol Rev 1962; 14: 447–72
Nahas GG. The clinical pharmacology of THAM, tris (hydroxymethyl)aminomethane. Clin Pharm Ther 1963; 4: 784–803
Nahas GG, editor. In vitro and in vivo effects of amine buffers. Ann NY Acad Sci 1961; 92: 333–812
Strauss J. Tris (hydroxymethyl) amino-methane (Tham): a pediatric evaluation. Pediatrics 1968; 41(3): 667–89
Pardee AB. Measurement of O2 uptake under controlled pressure of carbon dioxide. J Biol Chem 1949; 179: 1085–8
Krebs H. The use of ‘CO2 buffers’ in manometric measurements of cell metabolism. Biochem J 1951; 48: 349–59
Nahas G. Use of an organic carbon dioxide buffer in. vivo. Science 1959; 129: 782–3
Chernesky CE, Rodman JS, Reckler J, et al. Urothelial injury to the rabbit bladder from alkaline irrigants useful in the treatment of uric acid stones. J Urol 1987; 138(4): 893–4
Van Slyke D. On the measurement of buffer values and on the relationship of buffer value to the dissociation constant of the buffer and the concentration and reaction of the buffer solution. J Biol Chem 1922; 52: 525–70
Boron W. Chemistry of buffer equilibria in blood plasma. In: Seldin D, Giebisch G, editors. The regulation of acid-base balance. New York: Raven Press, 1989: 3–32
Jorgensen K, Astrup P. The effect of 2-amino-2-hydroxymethyl-1, 3-propanediol on blood-buffering capacity. Ann NY Acad Sci 1961; 92: 491–500
Bernard M, Menasche P, Canioni P, et al. Influence of the pH of cardioplegic solutions on intracellular pH, high-energy phosphates, and post-arrest performance: protective effects of acidotic, glutamate-containing cardioplegic perfusates. J Thorac Cardiovasc Surg 1985; 90: 235–42
Rahn H. Why are the pH of 7.4 and the PCO2 of 40 normal values for man? Bull Eur Physiopath Res 1976; 12: 5–13
Swan H. The importance of acid-base management for cardiac and cerebral preservation during open heart operations. Surg Gynecol Obstet 1984; 158: 391–414
Kresh JY, Nastala C, Bianchi PC, et al. The relative buffering power of cardioplegic solutions. J Thorac Cardiovasc Surg 1987; 93(2): 309–11
Gunn R. Buffer equilibria in red cells. In: Seldin D, Giebisch G, editors. The regulation of acid-base balance. New York: Raven Press, 1989: 57–67
Hearse D, Braimbridge M, Jynge P. Protection of the ischemic myocardium, cardioplegia. 3rd ed. New York: Raven Press, 1981: 263–99
Hindman BJ. Sodium bicarbonate in the treatment of subtypes of acute lactic acidosis: physiologic considerations. Anesthesiology 1990; 72(6): 1064–76
Arieff AI. Indications for use of bicarbonate in patients with metabolic acidosis [published erratum appears in Br J Anaesth 1992 Mar; 68 (3): 326]. Br J Anaesth 1991; 67(2): 165–77
Fraley D, Adler S. Correction of hyperkalemia by bicarbonate despite constant blood pH. Kidney Int 1977; 12: 354–60
Gutierrez R, Schlessinger F, Oster JR, et al. Effect of hypertonic versus isotonic sodium bicarbonate on plasma potassium concentration in patients with end-stage renal disease. Miner Electrolyte Metab 1991; 17(5): 297–302
Hiatt N, Hiatt J. Hyperkalemia and the electrocardiogram in dogs. Basic Res Cardiol 1988; 83: 137–40
Brown TC, Barker GA, Dunlop ME, et al. The use of sodium bicarbonate in the treatment of tricyclic antidepressant-induced arrhythmias. Anaesth Intensive Care 1973; 1: 203–10
Dziukas LJ, Vohra J. Tricyclic antidepressant poisoning. Med J Aust 1991; 154: 344–50
Hodes D. Sodium bicarbonate and hyperventilation in treating an infant with severe overdose of tricyclic antidepressant. BMJ 1984; 288(6433): 1800–1
Pentel PR, Benowitz NL. Tricyclic antidepressant poisoning: management of arrhythmias. Med Toxicol 1986; 1(2): 101–21
Sasyniuk BI, Jhamandas V, Valois M. Experimental amitriptyline intoxication: treatment of cardiac toxicity with sodium bicarbonate. Ann Emerg Med 1986; 15(9): 1052–9
Walsh DM. Cyclic antidepressant overdose in children: a proposed treatment protocol. Pediatr Emerg Care 1986; 2: 28–35
Arieff AI, Leach W, Park R, et al. Systemic effects of NaHCO3 in experimental lactic acidosis in dogs. Am J Physiol 1982; 242(6): F586–91
Bersin RM, Chatterjee K, Arieff AI. Metabolic and hemodynamic consequences of sodium bicarbonate administration in patients with heart disease [see comments]. Am J Med 1989; 87: 7–14
Clancy R, Cingolani H, Taylor R, et al. Influence of sodium bicarbonate on myocardial performance. Am J Physiol 1967; 212(4): 917–23
Cooper D, Walley K, Wiggs B, et al. Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis: a prospective, controlled clinical study. Ann Intern Med 1990; 112(7): 492–8
Graf H, Leach W, Arieff AI. Metabolic effects of sodium bicarbonate in hypoxic lactic acidosis in dogs. Am J Physiol 1985; 249: F630–5
Ostrea EM, Odell G.B. The influence of bicarbonate administration on blood pH in a ‘closed system’: clinical implications. J Pediatr 1972; 80: 671–80
Shapiro J, Whalen M, Kucera R, et al. Brain pH responses to sodium bicarbonate and carbicarb during systemic acidosis. Am J Physiol 1989; 256: H1316–21
Slack R, Nasraway S. Venous hypercarbia in circulatory failure. Intensive Crit Care Dig 1993; 12(1): 3–7
Sutin KM. Sodium bicarbonate does not correct respiratory acidosis [letter]. Lancet 1995; 346(8984): 1226–7
Weil M, Rackow E, Trevino R, et al. Difference in acid-base status between venous and arterial blood during cardiopulmonary resuscitation. N Engl J Med 1986; 315: 153–6
Maldonado F, Weil M, Tang W, et al. Myocardial hypercarbic acidosis reduces cardiac resuscitability. Anesthesiology 1993; 78: 343–52
Kette F, Weil M, Gazmuri R, et al. Intramyocardial hypercarbic acidosis during cardiac arrest and resuscitation. Crit Care Med 1993; 21(6): 901–6
Kette F, Weil M, von Planta M, et al. Buffer agents do not reverse intramyocardial acidosis during cardiac resuscitation. Circulation 1990; 81: 1660–6
Tang W, Weil M, Gazmuri B, J, et al. Reversible impairment of myocardial contractility due to hypercarbic acidosis in the isolated perfused rat heart. Crit Care Med 1991; 19(2): 218–24
von Planta M, Weil M, Gazmuri R, et al. Myocardial acidosis associated with CO2 production during cardiac arrest and resuscitation. Circulation 1989; 80: 684–92
Kette F, Weil M, Gazmuri R. Buffer solutions may compromise cardiac resuscitation by reducing coronary perfusion pressure. JAMA 1991; 266: 2121–6
Mark N, Leung J, Arieff A, et al. Evidence for a detrimental metabolic effect of sodium bicarbonate in operative patients with metabolic acidosis. Kidney Int 1990; 37: 267
Simmons M, Adcock III E, Bard H, et al. Hypernatremia and intracranial hemorrhage in neonates. N Engl J Med 1974; 291(6): 6–10
Graf H, Leach W, Arieff AI. Evidence for a detrimental effect of bicarbonate therapy in hypoxic lactic acidosis. Science 1985; 227: 754–6
Makisalo H, Soini H, Nordin A, et al. Effects of bicarbonate therapy on tissue oxygenation during resuscitation of hemorrhagic shock. Crit Care Med 1989; 17: 1170–4
Mattar J, Weil M, Shubinb H, et al. Cardiac arrest in the critically ill: II. Hyperosmolal states following cardiac arrest. Am J Med 1974; 56: 162–8
Holmdahl M, Nahas G, Hassam D, et al. Acid-base changes in the cerebrospinal fluid following rapid changes in the bicarbonate/carbonic acid ratio in blood. Ann NY Acad Sci 1961; 92: 520–7
Schneiderman R, Rosenkrantz TS, Knox I, et al. Effects of a continuous infusion of tris (hydroxymethyl)aminomethane on acidosis, oxygen affinity, and serum osmolality. Biol Neonate 1993; 64(5): 287–94
Mahler H. The use of amine buffers in studies with enzymes. Ann NY Acad Sci 1961; 92: 426–39
Ogle JD, Tytell AA. The activity of Clostridium histolyticum proteinase on synthetic substrates. Arch Biochem Biophys 1953; 42: 327–36
Packer EL, Hutner SH, Cox D, et al. Use of amine buffers in protozoan nutrition. Ann NY Acad Sci 1961; 92: 486–91
Swim H. Amine and other nonbicarbonate buffers in cell culture media. Ann NY Acad Sci 1961; 92: 440–6
Swim H, Parker R. Non-bicarbonate buffers in cell culture media. Science 1955; 122: 466
Rothstein A. Amine buffers and yeast. Ann NY Acad Sci 1961; 92: 470–8
Stormorken H, Newcomb T. The use of buffers in blood coagulation studies. Scand J Clin Lab Invest 1956; 8: 237–42
Prins GS, Weidel L. A comparative study of buffer systems as cryoprotectants for human spermatozoa. Fertil Steril 1986; 46(1): 147–9
McFarland W, Norris K. The use of amine buffers in the transportation of fishes. Ann NY Acad Sci 1961; 92: 446–56
Kylstra J, Tissing M, van der Maen A. Of mice as fish. Trans Am Soc Artif Intern Organs 1962; 8: 378–83
Clark LJ, Gollan F. Survival of mammals breathing organic liquids equlibrated with oxygen at atmospheric pressure. Science 1966; 152: 1755–6
Ogilvie JW, Whitaker SC. Reaction of Tris with aldehydes: effect of Tris on reactions catalyzed by homoserine dehydro-genase and glyceraldehyde-3-phosphate dehydrogenase. Biochim Biophys Acta 1976; 445(3): 525–36
Halliwell B, Gutteridge J. Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch Biochem Biophys 1986; 246(2): 501–14
Murphy PA, Lin JS, Oleott HS. Peroxide oxidation of Tris to a free radical. Arch Biochem Biophys 1974; 164: 776–7
Goldberg A, Schwartz I, Verosky M. Equilibrium dialysis of tris (hydroxymethyl)aminomethane (THAM) in serum and albumin. Fed Proc 1962; 21: 173
Schäcker M, Foth H, Schlüter J, et al. Oxidation of tris to one-carbon compounds in a radical-producing model system, in microsomes, in hepatocytes and in rats. Free Radic Res Commun 1991; 11(6): 339–47
Hall I. Effectiveness of THAM in preventing cellular damage resulting from oxygen lack. Proc Soc Exp Biol Med 1966; 122: 1240–5
Gibson GE, Shimada M, Blass JP. Protection by tris (hydroxymethyl)-aminomethane against behavioral and neurochemical effects of hypoxia. Biochem Pharmacol 1979; 28: 747–50
Nagao S, Kitaoka T, Fujita K, et al. Effect of tris-(hydroxymethyl)-aminomethane on experimental focal cerebral ischaemia. Exp Brain Res 1996; 111: 51–6
Brasch H, Thies E, Iven H. Pharmacokinetics of TRIS (hydroxymethyl-)aminomethane in healthy subjects and in patients with metabolic acidosis. Eur J Clin Pharmacol 1982; 22: 257–64
Gumbhir K, Mason WD. High-performance liquid Chromatographic method for the determination of tris (hydroxymethyl)aminomethane (tromethamine) in human plasma. J Chromatogr 1992; 583: 99–104
Hulshoff A, Kostenbauder HB. Gas Chromatographie method for the quantitative determination of tris (hydroxymethyl)aminomethane in plasma. J Chromatogr 1978; 145(1): 155–9
Morris MJ, Hsieh JY. Determination of tris (hydroxymethyl)aminomethane (tromethamine) in human plasma and urine by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1993; 622(1): 87–92
Brinkman G, Remp D, Coates E, et al. The treatment of respiratory acidosis with THAM. Am J Med Sci 1960; 239: 341–6
Nahas G, Verosky M, Schwartz I. Urinary excretion of THAM citrate orally administered. Proc Exp Biol Med 1964; 116: 378–82
Holmdahl M, Nahas G. Volume of distribution of C14 labeled tris (hydroxymethyl)aminomethane. Am J Physiol 1962; 202: 1011–4
Fenn W. Carbon dioxide and intracellular homeostasis. Ann NY Acad Sci 1961; 92(2): 547–58
Robin E, Wilson R, Bromberg P. Intracellular acid-base relations in intracellular buffers. Ann NY Acad Sci 1961; 92: 539–46
Telivuo L, Maamies T, Siltanen P, et al. Comparison of alkalizing agents in resuscitation of the heart after ventricular fibrillation. Ann Chir Gynaecol Fenn 1968; 57(2): 221–4
Rothe KF, Heisler N. Distribution of tris buffer between intracellular and extracellular space as a function of plasma pH in the rat. Acta Anaesthesiol Scand 1986; 30(2): 111–5
Gross GJ, Withrow CD. The uptake of 14C-THAM in various rat tissues. Arch Int Pharmacodyn Ther 1971; 190: 267–77
Epstein R, Nahas G, Mark L. Circulatory changes following rapid correction of severe hypercapnic acidosis by 2-amino-2-hydroxymethyl-1,3-propanediol. Ann NY Acad Sci 1961; 92(2): 500–7
Ligou J, Nahas G. Comparative effects of acidosis induced by acid infusion and CO2 accumulation. Am J Physiol 1960; 198: 1201–6
Nahas G, Reveillaud R, Strauss J, et al. Renal effect of tris (hydroxymethyl)aminomethane during CO2 load. Am J Physiol 1963; 204(1): 113–8
Gupta JM, Dahlenburg GW, Davis JA. Changes in blood gas tensions following administration of amine buffer THAM to infants with respiratory distress syndrome. Arch Dis Child 1967; 42: 416–27
Brown E, Greene D, Elam J, et al. Effects of 2-amino-2-hydroxymethyl-1,3-propanediol on CO2 elimination and production in normal man. Ann NY Acad Sci 1961; 92: 508–19
Peirce E. Effects of 2-amino-1-hydroxymethyl-1,3-propanediol (TRIS) during cardiac bypass procedures. Ann NY Acad Sci 1961; 92: 765–82
Roberts M, Linn S. Acute and subchronic toxicity of 2-amino-2-hydroxymethyl-1,3 propanediol. Ann NY Acad Sci 1961; 92(2): 724–34
Goldenberg VE, Wiegenstein L, Hopkins GB. Hepatic injury associated with tromethamine. JAMA 1968; 205: 81–4
Mihatsch MJ, Ohnacker H, Herzog B, et al. Bladder necrosis caused by use of THAM in a newborn infant. J Urol 1974; 111(6): 835–7
Adamsons Jr K, Behrman R, Dawes G, et al. The treatment of acidosis with alkali and glucose during asphyxia in foetal rhesus monkeys. J Physiol 1963; 169: 679–89
Holmdahl M. Pulmonary uptake of oxygen, acid-base metabolism and circulation during prolonged apnea. Acta Chir Scand 1956; 212: 1–128
Nahas GG, Jordan EC. Neutralization of the acute effects of hypercapnic acidosis by THAM. Aerospace Med 1960; 31: 61–8
Baratz R, Welter A, Hamilton L. Ventilatory, hemodynamic and renal response to I.V. infusions of CO2 with observations on the effects of a CO2 buffer. Fed Proc 1961; 20: 423
Millar RA, Bindle GF, Gilber RGB. Studies with an organic buffer (THAM) during apnoeic oxygenation in dogs. Br J Anaesth 1960; 32: 248–55
Benichoux R, Thibaut G, Marchai C. Les acidoses chirurgicales: experimentation d’un nouveau produit tampon. Le THAM. Presse Med 1961; 69: 2071
Nahas GG, Manger WM, Hassam D, et al. Effect of pH control and increased O2 delivery on the course of hemorrhagic shock. Fed Proc 1962; 21: 117
Nahas GG, Manger WM, Mittelman A. The use of 2-amino-2-hydroxymethyl-1,3-propanediol in the correction of addition acidosis and its effect on sympatho-adrenal activity. Ann NY Acad Sci 1961; 92: 596–617
Teschan PE, Lawson NL. Studies in acute renal failure. Prevention by osmotic diuresis, and observations on the effect of plasma and extracellular volume expansion. Nephron 1966; 3(1): 1–16
Samiy A, Oken D, Rees S, et al. Effect of 2-amino-2-hydroxymethyl-1,3-propanediol on electrolyte excretion. Ann NY Acad Sci 1961; 92: 570–8
Berman L, O’Connor T, Luchsinger P. CO2 buffering in man. J Appl Physiol 1960; 15: 343–6
Tarail R, Bennett T. Hypoglycemic activity of tris buffer in man and dog. Proc Soc Exp Biol Med 1959; 102: 208–9
Tarail R, Bennett T, Brown E, et al. Effects of THAM during CO2 breathing in man: metabolic and toxic effects. Physiologist 1959; 2(3): 114
Klamerus K, Munger M. Composition of cardioplegic solutions used in nine medical centers. Am J Hosp Pharm 1986; 43(6): 479–82
Luders AM, Brasch H, Iven H. Influence of Tris (hydroxymethyl) aminomethane on plasma insulin and glucose concentration of normal and streptozotocin-diabetic rats. Pharmacology 1984; 28: 216–22
Nahas GG, Dos SJ. L’influence du 2-amino-2-hydroxymethyl-1,3-propanediol sur le diabète pancréatique du chien. C R Acad Sci Paris 1960; 251: 1145–7
Bennett T, Tarail R. The hypoglycemic effect of 2-amino-2-hydroxymethyl-1,3-propanediol. Ann NY Acad Sci 1961; 92(2): 651–61
Buse M, Buse J, McMaster J, et al. The effect of Tris (hydroxymethyl) aminomethane on glucose utilisation of skeletal muscle. Metabolism 1964; 13: 339
Darby T. Effects of 2-amino-2-hydroxymethyl-1,3-propanediol during shock and catecholamine administration. Ann NY Acad Sci 1961; 92: 674–87
Darby T, Aldinger E, Thrower W, et al. Effects of tris (hydroxymethyl) aminomethane (THAM) on ventricular contractile force changes accompanying lactic acid infusion or elevation of ventilation CO2. Fed Proc 1960; 19: 674–87
Ng ML, Levy MN, Zieske HA. Effects of changes of pH and of carbon dioxide tension on left ventricular performance. Am J Physiol 1967; 213: 115–200
Thrower W, Darby T, Aldinger E. Acid-base derangements and myocardial contractility. Arch Surg 1961; 82: 56–65
Sirieix D, Delayance S, Paris M, et al. Tris-hydroxymethyl aminomethane and sodium bicarbonate to buffer metaboic acidosis in an isolated heart model. Am J Respir Crit Care Med 1997; 155: 957–63
Cline RE, Wallance AG, Sealy WC, et al. Antiarrhythmic properties of Tris (hydroxymethyl aminomethane). Am J Cardiol 1968; 21: 38–43
Wang H, Katz R. Effects of changes in coronary blood pH on the heart. Circ Res 1965; 17: 114
Tanaka T, Paton B, Swan H. The effects of tromethamine (Tris) on myocardial activity and metabolism. Surg Forum 1961; 12: 211–2
Burk D. On the use of carbonic anhydrase in carbonate and amine buffers for CO2 exchange in manometric vessels, atomic submarines and industrial CO2 scrubbers. Ann NY Acad Sci 1961; 92: 372–401
Ngai SH, Katz RL, Nahas GG, et al. Effects of 2-amino-2-hydroxymethyl-1,3-propanediol on the central respiratory mechanisms in the cat. Ann NY Acad Sci 1961; 92: 632–9
Ngai SH, Nahas GG, Wang SC. Effects of an organic buffer (THAM) on central respiratory mechanism in the cat. Fed Proc 1961; 20: 330
Luchsinger P, Berman L. Carbon dioxide buffering in pulmonary disease [abstract]. Clin Res 1960; 8: 255
Manfredi F, Sieker HO, Spoto AP, et al. Severe carbon dioxide intoxication. JAMA 1960; 173: 999–1003
Sieker H, Merwarth C, Saltzman H, et al. The use of 2-amino-2-hydroxymethyl-1,3-propanediol in severe carbon dioxide intoxication. Ann NY Acad Sci 1961; 92(2): 783–93
Swanson A. Potential harmful effects of treating pulmonary encephalopathy with a carbon dioxide buffering agent. Am J Med Sci 1960; 240: 433–7
Muir AL, Anderton JL, Lawrie DM, et al. Circulatory effects of digoxin, acid-base correction, and volume loading in cardiogenic shock. Br Heart J 1969; 31: 794
Nahas GG, Ligou JC, Mehlman B. Effects of pH changes on O2 uptake and plasma catecholamine levels in the dog. Am J Physiol 1960; 198: 60–6
Mittelman A, Dos SJ, Barker HG, et al. Adrenocortical response during corrected and unconnected hypercapnic acidosis. Br J Anaesth 1962; 32: 334–9
Dos S, Randolph W, Jacobson II J, et al. Effects of 2-amino-2-hydroxymethyl-1,3-propanediol on intracranial hypertension. Ann NY Acad Sci 1961; 92: 640–50
Dos S, Nahas G, Papper E. Experimental correction of hypercapnic intracranial hypertension. Anesthesiology 1962; 23: 46–50
Pfenninger E, Lindner K, Ahnefeld F. An infusion of THAM (trishydroxymethylaminomethane) as therapy to lower increased intracranial pressure in acute craniocerebral injuries. Anaesthetist 1989; 38(4): 189–92
Berenyi K, Wolk M, Killip T. Cerebrospinal fluid acidosis complicating therapy of experimental cardiopulmonary arrest. Circulation 1975; 52: 319–24
Posner J, Plum F. Spinal-fluid pH and neurologic symptoms in systemic acidosis. N Engl J Med 1967; 277: 605–13
Wagerle L, Kumar S, Belik J, et al. Blood brain barrier to hydrogen ion during metabolic acidosis in piglets. J Appl Physiol 1988; 65(2): 776–81
Gaab M, Knoblich O, Spohr A, et al. Effect of THAM on ICP, EEG, and tissue oedema parameters in experimental and clinical brain edema. In: Shulman K, Marmarou A, Miller J, et al., editors. Intracranial pressure IV. New York: Springer-Verlag, 1980; 664–8
Gaab M, Seegers K, Goetz C. THAM (tromethamine, ‘Tris-Buffer’): effective therapy of traumatic brain swelling? In: Hoff J, Betz A, editors. Intracranial pressure VII. New York: Springer-Verlag, 1989: 616–9
Kuyama H, Kitaoka T, Fujita K, et al. The effect of alkalinising agents on experimental focal cerebral ischaemia. Acta Neurochir Suppl. (Wien) 1994; 60: 325–8
Nahas GG, Gjessing J, Giroux JJ, et al. The passage of THAM across the peritoneum during dialysis. Clin Pharmacol Ther 1965; 6: 560–7
Holmdahl M. The use of tris (hydroxymethyl)aminomethane during short periods of apneic oxygenation in man. Ann NY Acad Sci 1961; 92(2): 794–801
Matell G. Organic CO2 buffer (THAM) in treatment of adrenalin-fast status asthmaticus. Opusc Med 1965; 10: 42–6
Holmdahl MH, Hedstrand U, Parrow A, et al. Association of artificial respiration and THAM in the treatment of status asthmaticus [in French]. Presse Med 1967; 75(19): 957–60
Mithoefer JC, Kazemi H, Holford FD, et al. Myocardial potassium exchange during respiratory acidosis: the interaction of carbon dioxide and sympathoadrenal discharge. Respir Physiol 1968; 5(1): 91–107
Bone R, Balk R, Cerra F, et al. American College of Chest Physicians/Society of Critical Care Medicine consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864–74
Knaus W, Draper E, Wagner D. APACHE II: a severity of disease classification system for acutely ill patients. Crit Care Med 1985; 13: 818
Ruokonen E, Takala J, Kari A, et al. Septic shock and multiple organ failure. Crit Care Med 1991; 19(9): 1146–51
Moore F, Moore E, Read R. Post injury multiple organ failure — role of extrathoracic injury and sepsis in adult respiratory distress syndrome. New Horiz 1993; 1: 538–492
Tuxen D, Williams T, Scheinkestel C, et al. Use of a measurement of pulmonary hyperinflation to control the level of mechanical ventilation in patients with severe asthma. Am Rev Respir Dis 1992; 146(5): 1136–42
Rupp S, Severinghaus J. Hypothermia. In: Miller R, editor. Anesthesia. New York: Churchill Livingstone, 1986: 1995–2022
Wetterberg T, Steen S. Combined use of hypothermia and buffering in the treatment of critical respiratory failure. Acta Anaesthesiol Scand 1992; 36: 490–2
Berntman L, Welsh F, Harp J. Cerebral protective effect of low-grade hypothermia. Anethesiology 1981; 55: 495–8
Bacalzo Jr LV, Wolfson Jr SK. Preferential cerebral hypothermia: tromethamine and dextran 40 and tolerance to circulatory arrest of 90 to 20. Arch Surg 103: 393–7
Pesenti A. Target blood gases during ARDS ventilatory management. Intensive Care Med 1990; 16: 349–51
Adamsons Jr K, Behrman R, Dawes G, et al. Resuscitation by positive pressure ventilation and tris-hydroxymethylaminomethane of rhesus monkeys asphyxiated at birth. J Pediatrics 1964; 65(6): 807–18
Dawes G, Hibbard E, Windle W The effect of alkali and glucose infusion on permanent brain damage in rhesus monkeys asphyxiated at birth. J Pediatrics 1964; 65(6): 801–6
Rudolph A, Yuan S. Response of the pulmonary vasculature to hypoxia and H+ ion concentration changes. J Clin Invest 1966; 45: 399–411
Van Vliet PK, Gupta JM. THAM v. sodium bicarbonate in idiopathic respiratory distress syndrome. Arch Dis Child 1973; 48(4): 249–55
Usher R. Reduction of mortality from respiratory distress syndrome of prematurity with early administration of intravenous glucose and sodium bicarbonate. Pediatrics 1963; 32: 966–75
Hobel C, Oh W, Hyvarinen M, et al. Early versus late treatment of neonatal acidosis in low-birth-weight infants: relation to respiratory distress syndrome. J Pediatr 1972; 81: 1178–87
Bell E. Fluid therapy: effects of early alkali therapy in prematurity. In: Sinclair J, Bracken M, editors. Effective care of the newborn infant. Oxford: Oxford University Press, 1992: 63–4
Bland RD, Clarke TL, Harden LB. Rapid infusion of sodium bicarbonate and albumin into high-risk premature infants soon after birth: a controlled, prospective trial. Am J Obstet Gynecol 1976; 124: 263–7
Bucci G, Medicini M, Scalamandre A, et al. A controlled trial on therapy for newborns weighing 750–1250g: part II. Blood chemistry and electrocardiographic observations in the newborn period. Acta Paediatr Scand 1971; 60: 417–27
Corbet AJ, Adams JM, Kenny JD, et al. Controlled trial of bicarbonate therapy in high-risk premature newborn infants. J Pediatr 1977; 91(5): 771–6
Duc G, Sinclair J. Oxygen administration: co-interventions. In: Sinclair J, Bracken M, editors. Effective care of the newborn infant. Oxford: Oxford University Press, 1992: 194–5
Medicini M, Scalamandre A, Savignoni P, et al. A controlled trial on therapy for newborns weighing 750–1250g: I. Clinical findings and mortality in the newborn period. Acta Pediatr Scand 1971; 60: 407–16
Sinclair J, Engel K, Silverman W. Early correction of hypoxemia and acidemia in infants of low birth weight: a controlled trial of oxygen breathing, rapid alkali infusion, and assisted ventilation. Pediatrics 1968; 42: 565–89
Tyson J. Immediate care of the newborn infant. In: Sinclair J, Bracken M, editors. Effective care of the newborn infant. Oxford: Oxford University Press, 1992: 31–2
Finberg L. The relationship of intravenous infusions and intracranial hemorrhage — a commentary. Clin Perinatol 1977; 91: 777–81
Kravath R, Aharon A, Abal G, et al. Clinically significant physiologic changes from rapidly administered hypertonic solutions: acute osmol poisoning. Pediatrics 1970; 46: 267–75
Levene MI, Fawer CL, Lamont RF. Risk factors in the development of intraventricular haemorrhage in the preterm neonate. Arch Dis Child 1982; 57: 410–7
Papile LA, Burstein J, Burstein R, et al. Relationship of intravenous sodium bicarbonate infusions and cerebral intraventricular hemorrhage. J Pediatr 1978; 93(5): 834–6
Rhodes PG, Hall RT, Hellerstein S. The effects of single infusion of hypertonic sodium bicarbonate on body composition in neonates with acidosis. J Pediatr 1977; 90(5): 789–95
Wigglesworth JS, Keith IH, Girling DJ, et al. Hyaline membrane disease, alkali, and intraventricular haemorrhage. Arch Dis Child 1976; 51: 755–62
Bureau M, Begin R, Berthiaume Y, et al. Cerebral hypoxia from bicarbonate infusion in diabetic acidosis. J Pediatr 1980; 96: 968–73
Lou HC, Lassen NA, Fris-Hansen B. Decreased cerebral blood flow after administration of sodium bicarbonate in the distressed newborn infant. Acta Neurol Scand 1978; 57: 239–47
Howell JH. Sodium bicarbonate in the perinatal setting — revisited. Clin Perinatol 1987; 14(4): 807–16
Kaplan S. Tris (hydroxymethyl)aminomethane (THAM) — a new buffer for therapeutic use. Am J Dis Child 1962; 103: 1–3
Troelstra J. Metabolism and acid base regulation in respiratory distress syndrome; treatment with tri-hydroxymethyl aminomethane (THAM). Maandschr Kindergeneeskd 1964; 32: 569–85
Ewerbeck H. Tris buffer therapy of metabolic acidosis in toxic gastroenteritis in infants and in the respiratory disorders of the newborn (‘fetal distress’ syndrome) [in German]. Dtsch Med Wochenschr 1965; 90(45): 1989–94
Rumler W, Sitka U. Acidosis in infantile toxicosis and its treatment with THAM [in German]. Z Kinderheilkd 1968; 103: 52–60
Larcan A, Herbeuval R. Le THAM en diabétologie. Ann Anesthesiol Fr 1966; 7: 887–94
Neimann N, Vert P, Marchai C, et al. Les application du THAM en pédiatrie. Ann Anesthesiol Fr 1966; 7: 861–77
Vert P, Marchai C, Neimann N, et al. Symptomatic treatment of renal acidosis by oral administration of THAM citrate [in French]. Arch Fr Pediatr 1968; 25(1): 91–102
Oliver T. The use of THAM in the titration of ACD blood in exchange transfusion of high-risk infants. Pediatrics 1967; 68: 125
Ornato JP, Gonzalez ER, Coyne MR, et al. Arterial pH in out-of-hospital cardiac arrest: response time as a determinant of acidosis. Am J Emerg Med 1985; 3(6): 498–502
Bleich H, Schwartz W Tris buffer (Tham): an appraisal of its physiologic effects and clinical usefulness. N Engl J Med 1966; 274: 782
Roberton NR. Apnoea after THAM administration in the newborn. Arch Dis Child 1970; 45(240): 206–14
Berg D, Mulling M, Saling E. Use of THAM and sodium bicarbonate in correcting acidosis in asphyxiated newborns. Arch Dis Child 1960; 44: 318–22
Devlieger H, Snoeys R, Wyndaele L, et al. Liver necrosis in the new-born infant: analysis of some precipitating factors in neonatal care. Eur J Pediatr 1982; 138(2): 113–9
Nahas GG. Hepatic injury related to tromethamine [letter]. JAMA 1968; 206: 1793
Nessler G. Treatment of diabetic acidosis with tris buffer [in German]. Arch Kinderheilkd 1969; 178: 240–57
Kaplan S, Fox R, Clark L. Amine buffers in the management of acidosis: study of respiratory and mixed acidosis. Am J Dis Child 1962; 103: 4–9
Malm JR, Bowman FO, Sullivan SF, et al. The use of THAM buffered acid-dextrose-citrate blood for extracorporeal circulation. J Cardiovasc Surg 1965; 6: 134
Malm JR, Manger WM, Sullivan SF, et al. The effect of acidosis on sympatho-adrenal stimulation: particular reference to cardiopulmonary bypass. JAMA 1966; 197(2): 121–5
Moore D, Bernhard W. Efficacy of 2-amino-2-hydroxymethyl-1,3-propanediol (Tris buffer) in management of metabolic lacticacidosis accompanying prolonged hypothermic perfusions. Surgery 1962; 52: 905–14
Nahas G, Malm J, Manger W, et al. Control of acidosis and the use of titrated ACD blood in open-heart surgery. Ann Surg 1964; 160(6): 1049–56
Stahlman M. Treatment of cardiovascular disorders of the newborn. Pediatr Clin North Am 1964; 11: 363
Bircher N. Physiology and pharmacology of standard cardiopulmonary resuscitation. In: Kaye W, Ng B, editors. Cardiopulmonary resuscitation. New York: Churchill Livingstone, 1989: 55–86
Chazan J, Stenson R, Kurland G. The acidosis of cardiac arrest. N Engl J Med 1968; 278: 360–4
Edmonds-Seal J. Acid-base studies after cardiac arrest: a report of 64 cases. Acta Anaesthesiol Scand 1966; 12 Suppl.: 77–95
Fillmore S, Shapiro M, Killip T. Serial blood gas studies during cardiopulmonary resuscitation. Ann Intern Med 1970; 72: 465–9
Henneman P, Gruber J, Marx J. Development of acidosis in human beings during closed-chest and open-chest CPR. Ann Emerg Med 1988; 17: 672–5
Redding J, Pearson J. Metabolic acidosis: a factor in cardiac resuscitation. South Med J 1967; 60: 926–32
Rubertsson S, Wiklund L. Hemodynamic effects of epinephrine in combination with different alkaline buffers during experimental, open-chest, cardiopulmonary resuscitation. Crit Care Med 1993; 21(7): 1051–7
Suljaga-Pechtel K, Goldberg E, Strickon P, et al. Cardiopulmonary resuscitation in a hospitalized population: prospective study of factors associated with outcome. Resuscitation 1984; 12(2): 77–95
Wiklund L, Jorfeldt L, Stjernstrom H, et al. Gas exchange as monitored in mixed venous and arterial blood during experimental cardiopulmonary resuscitation. Acta Anaesthesiol Scand 1992; 36(5): 427–35
American Heart Association. Standards and guidelines for cardiopulmonary resuscitation and emergency cardiac care. JAMA 1986; 268: 2841–3044
Kirimli B, Harris L, Safar P. Sodium bicarbonate and epinephrine in cardiac resuscitation. Anesthesiology 1964; 25: 105
Ledingham I, Norman J. Acid-base studies in experimental cardiac arrest. Lancet 1962; II: 967–9
Redding J, Pearson J. Resuscitation from ventricular fibrillation: drug therapy. JAMA 1968; 203: 255–60
Vukmir R, Nicholas G, Radovsky A. Sodium bicarbonate may improve outcome of dogs with brief or prolonged cardiac arrest. Crit Care Med 1995; 23(3): 515–22
Wiklund L, Ronquist G, Stjernstrom H, et al. Effects of alkaline buffer administration on survival and myocardial energy metabolism in pigs subjected to ventricular fibrillation and closed chest CPR. Acta Anaesthesiol Scand 1990; 34: 430–9
Effron MB, Guarnieri T, Frederiksen JW, et al. Effect of tris (hydroxymethyl)aminomethane on ischemic myocardium. Am J Physiol 1978; 235: H167–74
von Planta M, Gudipati C, Weil MH, et al. Effects of tromethamine and sodium bicarbonate buffers during cardiac resuscitation. J Clin Pharmacol 1988; 28(7): 594–9
Wexels J, Mjos O. Effects of carbon dioxide and pH on myocardial function in dogs with acute left ventricularfailure. Crit Care Med 1987; 15: 1116–20
Wiklund L, Oquist L, Skoog G, et al. Clinical buffering of metabolic acidosis: problems and a solution. Resuscitation 1985; 12(4): 279–93
Neethling WM, van den Heever JJ, Cooper S, et al. Interstitial pH during myocardial preservation: assessment of five methods of myocardial preservation. Ann Thorac Surg 1993; 55: 420–6
Bleese N, Doring V, Kalmar H, et al. Intraoperative myocardial protection by cardioplegia in hypothermia. J Thorac Cardiovasc Surg 1978; 75: 405–13
Tait GA, Booker PD, Wilson GJ, et al. Effect of multidose cardioplegia and cardioplegic solution buffering on myocardial tissue acidosis. J Thorac Cardiovasc Surg 1982; 83(6): 824–9
Arieff A. Hypoxia, metabolic acidosis, and the circulation. In: Arieff A, editor. Hypoxia, metabolic acidosis, and the circulation. New York, Oxford: Oxford University Press, 1992: 118–20
Buckberg G. A proposed ‘solution’ to the cardioplegic controversy. J Thorac Cardiovasc Surg 1979; 77: 803–15
Turlapaty PD, Altura BT, Altura BM. Influence of tris on contractile responses of isolated rat aorta and portal vein. Am J Physiol 1978; 235(2): H208–13
Gillespie JS, McKnight AT. Adverse effects of tris hydrochloride, a commonly used buffer in physiological media. J Physiol (Lond) 1976; 259(2): 561–73
Martin D. Fluid and electrolyte balance during liver transplantation in hepatic transplantation. In: Winter P, Kang Y, editors. Anesthetic and perioperative management. Westport (CT): Praeger, 1986: 19–32
Wildenthal K, Mierzwiak DS, Myers RW, et al. Effects of acute lactic acidosis on left ventricular performance. Am J Physiol 1968; 214: 1352–9
Plevak D, Southorn P, Narr B, et al. Intensive-care unit experience in Mayo liver transplantation program: the first 100 cases. Mayo Clin Proc 1989; 64(4): 433–45
Estol C, Faris A, Martinez J. Central pontine myelinolysis after liver transplantation. Neurology 1989; 39: 493–98
Hale PJ, Crase J, Nattrass M. Metabolic effects of bicarbonate in the treatment of diabetic ketoacidosis. BMJ 1984; 289(6451): 1035–8
Lever E, Jaspan JB, Strel’chuk IV. Sodium bicarbonate therapy in severe diabetic ketoacidosis. Am J Med 1983; 75: 263–8
Morris L, Murphy M, Kitabchi A. Bicarbonate therapy in severe diabetic ketoacidosis. Ann Intern Med 1986; 105: 836–40
Ohman J, Masliss E, Aoki T, et al. The cerebrospinal fluid in diabetioc ketoacidosis. N Engl J Med 1971; 284: 283–90
Touchard P, Le Berre JR Value of THAM in the treatment of acido-ketosis diabetic coma [in French]. Anesth Analg (Paris) 1969; 26(1): 25–47
Rees S, Younger M, Freedlander A. Some in. vivo and in vitro observations on the effects of tris (hydroxymethyl)amino methane in diabetic acidosis. Ann NY Acad Sci 1961; 92: 539–46
Niemann N, Vert P, Marchai C, et al. Les applications du THAM en pédiatrie. Ann Anesthesiol Fr 1966; 7(4): 861–76
Samiy A, Ramsay A, Rees S, et al. The use of 2-amino-2-hydroxymethyl-1,3-propanediol in the management of renal acidosis. Ann NY Acad Sci 1961; 92: 803–12
Quellhorst E, Heimburg P, Willms B, et al. Studies on the use of tris-buffer in severe kidney insufficiency [in German]. Klin Wochenschr 1966; 44(21): 1243–7
Poli D, Maschio G, Todesco S, et al. Comparative effects of THAM (tris-hydroxymethyl-amino-methane) and sodium bicarbonate in the therapy of renal acidosis [in Italian]. Minerva Nefrol 1968; 15(4): 267–72
Cramer L, Hinshaw J. Further experience in the use of tris buffer in the treatment of severely burned patients. Plast Reconstr Surg 1965; 35: 76–84
Zimmermann W. Der Trispufer in klinischer Anwendung. Dtsch Med Wochenschr 1963; 88: 1305–18
Gaab MR, Seegers K, Smedema RJ, et al. A comparative analysis of THAM (Tris-buffer) in traumatic brain oedema. Acta Neurochir Suppl (Wien) 1990; 51(3): 320–3
Knoblich O, Gaab M, Fuhrmeister U, et al. Comparison of the effects of osmotherapeutic agents, hyperventilation and tromethamine (THAM) on brain pressure and electric activity of the brain in experimental and clinical brain edema. In: Frowein R, editor. Advances in neurosurgery. Vol. 5. New York: Springer-Verlag, 1978: 336–45
Marmarou A. Intracellular acidosis in human and experimental brain injury. J Neurotrauma 1992; 9 Suppl. 2: S551–62
Wolf AL, Levi L, Marmarou A, et al. Effect of THAM upon outcome in severe head injury: a randomized prospective clinical trial. J Neurosurg 1993; 78: 54–9
Muizelaar JP, Marmarou A, Ward JD, et al. Adverse effects of prolonged hyperventilation in patients with severe head injury: a randomized clinical trial. J Neurosurg 1991; 75: 731–9
Robertson C, Clifton G, Grossman R. Oxygen utilization and cardiovascular function in head-injured patients. Neurosurgery 1984; 15: 307–14
Rosner MJ, Becker DP. Experimental brain injury: successful therapy with the weak base, tromethamine. With an overview of CNS acidosis. J Neurosurg 1984; 60(5): 961–71
Yoshida K, Marmarou A. Effects of tromethamine and hyperventilation on brain injury in the cat. J Neurosurg 1991; 74(1): 87–96
Rosner M, Elias K, Coley I. Prospective, randomized trial of THAM therapy in severe brain injury: preliminary results. In: Hoff J, Betz A, editors. Intracranial pressure. Vol. 7. New York: Springer-Verlag, 1989: 611–6
Rietbrock N, Herken W, Henschler D. Effect of Tris buffer (THAM) and sodium bicarbonate on the metabolic acidosis of methanol poisoning in dogs [in German]. Arch Toxikol 1969; 24(2): 229–34
Hickling KG, Henderson SJ, Jackson R. Low mortality associated with low volume pressure limited ventilation with permissive hypercapnia in severe adult respiratory distress syndrome. Intensive Care Med 1990; 16(6): 372–7
Strauss J, Nahas G. Use of amine buffer (THAM in the treatment of acute salicylate intoxication). Proc Soc Exp Biol 1960; 105: 348–51
Clark LJ. Treatment of salicylate poisoning with tris buffer. Trans Am Soc Artif Intern Organs 1960; 6: 253
Gemmill W, Sechrist G, Oliver TJ, et al. The use of tris buffer to alkalinize the urine of young children with severe salicylism [abstract]. J Pediat 1963; 63: 732
deGennes L, Réveillaud R, Patte D. Intoxication barbiturique aiguë survenant chez une hypertendue. Traitement par le THAM. Bull Soc Med Paris 1962; 113: 1002–9
Genefke IK, Mantz JM, Tempe JD. THAM used in the treatment of barbiturate coma [in Danish]. Ugeskr Laeger 1968; 130: 761–2
Knochel J, Barry K. THAM dialysis: an experimental method to study diffusion of certain weak acids in vivo. II: secobarbital. J Lab Clin Med 1965; 65(3): 361–9
Knochel J, Clayton L, Smith W, et al. Intraperitoneal THAM: an effective method to enhance phenobarbital removal during peritoneal dialysis. J Lab Clin Med 1964; 64(2): 257–68
Knochel JP, Mason AD. Effect of alkalinization on peritoneal diffusion of uric acid. Am J Physiol 1966; 210(5): 1160–4
Gjessing J, Giroux JJ, Mark LC, et al. L’utilisation du THAM dans la dialyse péritonéale au cours des intoxications aiguës: étude experimentale et clinique. Ann Anesthesiol Fr 1966; 7(4): 913–23
Auzepy P, Taktak H, Toubas PL, et al. Acute ethylene glycol and diethylene glycol poisoning in adults: 2 cases with recovery [in French]. Sem Hop 1973; 49(19): 1371–4
Pentel P, Benowitz N. Efficacy and mechanism of action of sodium bicarbonate in the treatment of desipramine toxicity in rats. J Pharmacol Exp Ther 1984; 230(1): 12–9
Crowell A. Cystine nephrolithiasis, report of case with roentgenographic demonstration of disintegration of stone by alkalinization. Surg Gynecol Obstet 1924; 38: 87
Reveillaud RJ. Le THAM oral dans les lithiases radio-transparentes et les insuffisances rénales. Ann Anesthesiol Fr 1966; 7(4): 895–908
Dretler SP, Pfister RC, Newhouse JH, et al. Percutaneous catheter dissolution of cystine calculi. J Urol 1984; 131(2): 216–9
Crissey MM, Gittes RF. Dissolution of cystine ureteral calculus by irrigation with tromethamine. J Urol 1979; 121(6): 811–2
Berkhoff WB, van Haga JJ, Roodvoets AR Percutaneous chemolitholysis of cystine stones: possibilities for ambulatory procedure. Eur Urol 1988; 14: 168–70
Hara Y, Tozuka K, Moriguchi H, et al. Percutaneous dissolution of uric acid and cystine stones causing acute ureteral obstruction [in Japanese]. Hinyokika Kiyo 1990; 36(11): 1271–6
Kachel TA, Vijan SR, Dretler SP. Endourological experience with cystine calculi and a treatment algorithm. J Urol 1991; 145(1): 25–8
Lee YH, Chang LS, Chen MT, et al. Experience with percutaneous nephrostomy, extracorporeal shock wave lithotripsy and chemolysis in the treatment of obstructive uric acid stones. Eur Urol 1991; 19: 209–12
Newhouse JH, Pfister RC. Therapy for renal calculi via percutaneous nephrostomy: dissolution and extraction. Urol Radiol 1981; 2: 165–70
Tseng CH, Talwalkar YB, Tank ES, et al. Dissolution of cystine calculi by pelviocaliceal irrigation with tromethamine-E. J Urol 1982; 128(6): 1281–4
Lee YH, Chang LS, Chen MT, et al. Local chemolysis of obstructive uric acid stone with 0.1 M THAM and 0.02% chlorhexidine. Urol Int 1993; 51: 147–51
Rosenberg H. Clinical presentation of malignant hyperthermia. Br J Anaesth 1988; 60: 268–73
Bull AB, Harrison GG. Recent advances in the understanding of anaesthetic-induced malignant hyperpyrexia. Acta Anaesthesiol Belg 1973; 24: 97–108
Gronert GA, Antogini JF. Malignant hypothermia. In: Miller RD, editor. Anesthesia, 4th edition. New York: Churchill Livingstone, 1994: 1075–93
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article is available at http://dx.doi.org/10.1007/BF03259987.
Rights and permissions
About this article
Cite this article
Nahas, G.G., Sutin, K.M., Fermon, C. et al. Guidelines for the Treatment of Acidaemia with THAM. Drugs 55, 191–224 (1998). https://doi.org/10.2165/00003495-199855020-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199855020-00003